SPR® Therapeutics Unveils Long-term Data on SPRINT® PNS and Initial MONARCH™ Trial Update
July 15, 2024 09:05 ET
|
SPR Therapeutics, Inc.
SPR Therapeutics announced the presentation of five abstracts at the ASPN Annual Conference including four-year data on SPRINT PNS.
New Publication Reviewing Percutaneous PNS in the Management of Chronic Pain Highlights Consistent, Sustained Relief of Pain Across Multiple Targets
June 11, 2024 12:47 ET
|
SPR Therapeutics, Inc.
New Publication on Percutaneous PNS in the Management of Chronic Pain Highlights Consistent, Sustained Relief of Pain Across Multiple Targets
SPR® Therapeutics Announces $85 Million in Additional Funding to Advance Rapid Commercial Expansion of the SPRINT® PNS System
February 01, 2024 09:00 ET
|
SPR Therapeutics, Inc.
SPR Therapeutics Announces $85 Million in Additional Funding to Advance Commercial Expansion of SPRINT PNS System.
SPR® Therapeutics Announces Extensive Set of Abstracts to be Shared at North American Neuromodulation Society (NANS) Annual Meeting 2024
January 16, 2024 09:00 ET
|
SPR Therapeutics, Inc.
SPR Therapeutics and the SPRINT PNS System will be featured prominently at the North American Neuromodulation Society Annual Meeting with 11 abstracts.
New SPR Therapeutics Data Presented at ASRA Pain Medicine Meeting 2023
November 13, 2023 09:05 ET
|
SPR Therapeutics, Inc.
Three SPR Posters Accepted Including a President’s Choice Award for New Data from Randomized Controlled Trial on Total Knee Replacement Postoperative Pain
Pain Awareness Month: Psychable Educates Patients on Transformative Power of Using Psychedelics as Medicine for Pain Treatment, Management and Healing
September 15, 2021 20:30 ET
|
Psychable, Inc.
LOS ANGELES, Sept. 15, 2021 (GLOBE NEWSWIRE) -- September is Pain Awareness Month. Affecting more than 50 million Americans, chronic pain - both unmanaged and unmanaged, physical and emotional - is...